Usana misses, issues guidance

 

Usana Health Sciences misses Q2 2026 estimates with non-GAAP EPS -$0.07 and revenue $223.3M

• Non-GAAP EPS -$0.07 was down 109% year over year from the prior-year quarter.
• Q2 revenue of $223.3M declined 5% year over year from the prior-year period.
• Company reported a Q2 2026 GAAP loss of $1.16 per share.
• Company now guides for full-year EPS of $0.76 on revenue of $910M.

https://finviz.com/stock?t=USNA&p=d